MannKind Corporation said last week it picked up ex-Insulet (NSDQ:PODD) CEO Duane DeSisto as its new prez and CEO, effective January 5, 2016. DeSisto will replace interim CEO Alfred Mann, who has held the spot since November.
DeSisto will also join the company’s board of directors, according to a press release from the Valencia, Calif.-based company.
“Duane is a respected industry veteran with a strong track record of developing and commercializing disruptive technology for the management of diabetes. Duane’s experience will be instrumental as we seek to enhance the commercial opportunity for Afrezza and pursue additional product opportunities within our pipeline. We are excited to welcome Duane to the team and look forward to his leadership,” Mann said in a press release.
DeSisto served as prez and CEO of Insulet from 2003 to 2014, and held CFO and treasurer positions at the company prior to that. Before his time at Insulet, DeSisto worked at pulp and paper industry company PaperExchange.com, accessories wholesaler FGX International Holdings Limited and Zoll Medical.
“I am thrilled to be joining MannKind and I look forward to working with the Board and leadership team to help Afrezza realize its full potential. MannKind has world-class pharmaceutical technology that has the potential to address a large number of unmet medical needs, and I am excited by the opportunities at MannKind for creating significant value for our shareholders,” DeSisto said in prepared remarks.
ViewRay adds Avedro CFO/COO Roberts to board
Viewray said it added Avedro CFO/COO Brian Roberts to its board of directors. Roberts will serve as the chair of the audit committee for the board, the company said.
Nephros chair Centella retires
Nephros (OTC:NEPH) said yesterday its board chairman Lawrence Centella, who has served in the position since April, will retire from the position effective today.
Delphinus adds venture managing directors Neis, Fulton to board
Delphinus said earlier this month it added Venture Investors managing director John Neis and Hopen Life Science Ventures managing director Michael Fulton to its board.